FDA Office of Generic Drugs 2022 annual report

In 2022, generic drugs remained a significant public health priority for the US Food and Drug Administration (FDA), the agency announced yesterday, along with publishing its 2022 Office of Generic Drugs (OGD) Annual Report.

Generic drug approvals often mean more stability for the supply of medicines and a reduced risk of drug shortages. It is estimated that 91% of all prescriptions in the USA filled as generic drugs, with more than 32,000 generic drugs approved by FDA to date.

The FDA noted that it approved hundreds of abbreviated new drug applications (ANDAs), thousands of ANDA supplements, and funded approximately $20 million in generic drug science and research programs in 2022.